Akebia Therapeutics Inc. (AKBA)
Akebia Therapeutics, Inc. (AKBA) Q2 2025 Earnings Call Transcript
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q2 2025 Earnings Conference Call August 7, 2025 8:00 AM ET Company Participants Erik John Ostrowski - Chief Business Officer, Senior VP, CFO & Treasurer John P. Butler - CEO, President & Director Mercedes Carrasco - Senior Director of Investor & Corporate Communications Nicholas Grund - Senior VP & Chief Commercial Officer Conference Call Participants Julian Reed Harrison - BTIG, LLC, Research Division Mazahir Lukman Alimohamed - Leerink Partners LLC, Research Division Roger Song - Jefferies LLC, Research Division Operator Good day and thank you for standing by.
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q2
Akebia Therapeutics (AKBA) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.04 per share a year ago.
Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year?
Here is how Akebia Therapeutics (AKBA) and Alignment Healthcare (ALHC) have performed compared to their sector so far this year.
Akebia Therapeutics (AKBA) Upgraded to Strong Buy: Here's What You Should Know
Akebia Therapeutics (AKBA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year?
Here is how Akebia Therapeutics (AKBA) and ResMed (RMD) have performed compared to their sector so far this year.
Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director of Investor Relations John Butler - Chief Executive Officer Nick Grund - Chief Commercial Officer Erik Ostrowski - Chief Financial and Chief Business Officer Conference Call Participants Roanna Ruiz - Leerink Partners Roger Song - Jefferies Allison Bratzel - Piper Sandler Les Siloski - Truist Securities Operator Good day and thank you for standing by. Welcome to Akebia's First Quarter 2025 Financial Results Call.
Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates
Akebia Therapeutics (AKBA) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.09 per share a year ago.
Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy?
Akebia Therapeutics (AKBA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock
Akebia Therapeutics (AKBA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering
AKBA's shares fell after announcing the pricing of its secondary issue of shares, which were at a discount to the previous closing price.
Akebia Therapeutics, Inc. (AKBA) Q4 2024 Earnings Call Transcript
Akebia Therapeutics, Inc. (NASDAQ:AKBA ) Q4 2024 Earnings Conference Call March 13, 2025 8:00 AM ET Company Participants Mercedes Carrasco - Senior Director, IR John Butler - CEO Nick Grund - Chief Commercial Officer Erik Ostrowski - Chief Financial & Business Officer Conference Call Participants Allison Bratzel - Piper Sandler Julian Harrison - BTIG Ed Arce - H.C. Wainwright Operator Good day, and welcome to Akebia's Fourth Quarter 2024 Financial Results Call.
Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to break-even earnings per share a year ago.
